Background {#Sec1}
==========

Total hip replacement (THR) is the most successful surgical procedure for treating patients with hip arthritis \[[@CR1]\]. 332,000 THRs are performed annually in the United States \[[@CR2]\] with numbers expected to increase rapidly \[[@CR3], [@CR4]\]. Revision surgery for failed THR remains a significant problem, especially in young patients with high activity levels, with the future revision burden also expected to substantially increase \[[@CR3]--[@CR6]\].

Modifications were made to traditional THRs with metal-on-polyethylene bearing surfaces in an attempt to improve implant longevity and patient function. These included newer bearing surfaces with larger femoral head sizes, which aimed to reduce bearing wear and dislocation risk, whilst increasing hip movement. Furthermore, modular implants were an attractive concept to surgeons as they provided more flexibility in terms of helping to restore patient anatomy and optimising hip biomechanics \[[@CR7]\]. As a result large-diameter metal-on-metal (MoM) bearing surfaces became popular with approximately 1.5 million of these designs implanted worldwide in young and active patients. However, MoM hips experienced high short-term failure rates \[[@CR8], [@CR9]\] with many revisions performed for adverse reactions to metal debris (ARMD) \[[@CR10], [@CR11]\]. The aetiology of ARMD remains incompletely understood. Initially excessive bearing wear was considered to be responsible, but more recently wear and corrosion at modular THR junctions has been implicated \[[@CR12]--[@CR14]\]. ARMD lesions are often invasive and destructive \[[@CR10], [@CR11]\], with poor outcomes reported following revision surgery \[[@CR15]\]. Worldwide regulatory authorities therefore recommend regular follow-up for MoM hip patients \[[@CR16], [@CR17]\].

The three main bearing surfaces currently used in THR are metal-on-polyethylene, ceramic-on-ceramic, and ceramic-on-polyethylene \[[@CR18], [@CR19]\]. Recently ARMD requiring revision surgery has been observed in non-MoM THRs \[[@CR20]--[@CR24]\]. Small studies have reported between 7 and 27 ARMD revisions in non-MoM THRs, which mainly occurred in newer implant designs with large femoral heads \[[@CR20]--[@CR24]\]. One study estimated that 0.25% of consecutive non-MoM THRs (12 of 4813) implanted at their centre subsequently required revision for ARMD \[[@CR23]\]. However, the true risk of revision surgery for ARMD in non-MoM THRs remains unknown.

The National Joint Registry (NJR) for England, Wales, Northern Ireland and the Isle of Man was established in 2003 to identify poorly performing implants early, and represents the world's largest arthroplasty registry \[[@CR18]\]. We assessed all hip replacements undergoing revision surgery for ARMD recorded in the NJR. The study aims were to: (1) determine the risk of ARMD revision surgery in all non-MoM hip replacements, and (2) compare patient and surgical factors associated with ARMD revision between non-MoM hip replacements and MoM hip replacements.

Methods {#Sec2}
=======

We performed a retrospective observational study using data from the NJR for England, Wales, Northern Ireland and the Isle of Man. The NJR contains details of all primary and revision hip replacement procedures performed since April 2003. The present study was based on a subgroup of 3,433 hip replacements known to have required revision surgery for ARMD up until the 18^th^ November 2015. At the time this dataset was acquired the NJR had recorded a total of 889,340 primary hip replacement procedures.

Numerous terms have been used to describe abnormal destructive reactions related to MoM hip replacements that require revision surgery. These include ARMD \[[@CR11], [@CR14]\], pseudotumour \[[@CR10]\], aseptic lymphocytic vasculitis-associated lesions \[[@CR25]\], and adverse local tissue reaction \[[@CR26]\]. These terms are often used interchangeably to describe the same process. In June 2008, the NJR first introduced the term ARMD for surgeons to select as an indication for revision surgery, given ARMD is considered the most inclusive term for these abnormal reactions \[[@CR11], [@CR14]\]. The present study includes all primary hip replacements revised for ARMD between 1st June 2008 and 18th November 2015, which have been recorded in the NJR.

By using unique patient identifiers all 3,433 revision procedures for ARMD could be linked to the primary hip replacement procedure. For both the primary and revision procedures the NJR collects data on patient demographics (age, gender, body mass index, American Society of Anesthesiologists (ASA) grade, indication for surgery, venous thromboembolism prophylaxis), surgery performed (surgeon grade, surgical approach, details of components implanted including the bearing surface, component size, and implant fixation), and intra-operative adverse surgical events (calcar crack; pelvic and/or femoral shaft penetration; trochanteric and/or femoral shaft fracture; other), which were all available for analysis in the present study. In addition, NJR data on revision procedures provided detailed information on intra-operative findings, including reason(s) for revision surgery. After linking primary and revision procedures the bearing surface implanted at the primary surgery could not be clearly identified in 93 cases. These were excluded, leaving 3,340 hip revisions performed for ARMD in the final study cohort for analysis. Conventional methods for describing bearing surfaces were used, for example metal-on-polyethylene represents a metal femoral head articulating with a polyethylene liner or socket.

Statistical analysis {#Sec3}
--------------------

The cohort was divided into two groups based on whether the primary hip replacement bearing surface was non-MoM or MoM. The MoM group included both stemmed THRs and hip resurfacings. Subsequent analyses were separated into two distinct parts to reflect the study aims.

### Risk of ARMD revision surgery in non-MoM hip replacements {#Sec4}

To calculate the risk of ARMD revision surgery, observational data for all hip replacements revised for ARMD as recorded in the NJR were available as the numerator. Complete clinical data on all hip replacements not undergoing revision surgery were not available. For the denominator, data from the NJR were provided on the total number of primary hip replacements performed as a whole, and for different bearing surfaces and femoral head sizes. Hence it was possible to calculate the risk of ARMD revision surgery for the whole NJR population, and for each bearing surface and femoral head size subgroup. The relative risk of ARMD revision between different non-MoM bearing surfaces and femoral head sizes were compared using the Chi-squared test with Yates' correction.

### Comparison of patient and surgical factors associated with ARMD revision between non-MoM and MoM hip replacements {#Sec5}

Patients were selected for this study based on their final outcome, i.e., revision of a primary hip replacement for ARMD. Patient and surgical factors (for both the primary hip replacement and the revision surgery for ARMD) were subsequently compared between non-MoM hip replacements (cases) and MoM hip replacements (controls). Data from all numerical co-variates were normally distributed and compared using unpaired *t*-tests, with categorical data assessed using either the Chi-squared test with Yates' correction or Fisher's exact test. Time to ARMD revision surgery was also assessed using the Kaplan-Meier method, with a univariate Cox proportional hazards model used to compare time to revision by type of primary bearing surface. As the analysis only included observational data on hip replacements revised for ARMD, the different primary bearing surface groups in this Cox model all reached a survival probability of zero. Multivariable logistic regression modeling was used to assess the effect of patient demographics (age, gender, ASA grade, indication for primary surgery, time to revision surgery) on the binary outcome variable (whether an ARMD revision was performed in a non-MoM or MoM hip replacement). Surgical factors (such as surgical approach, component size, and implant fixation) were not included in the logistic regression models given these factors are almost completely determined by the initial decision to perform either a primary non-MoM or MoM hip replacement, hence these surgical factors are part of the causal pathway \[[@CR9]\]. When assessing patient demographics in the logistic regression models, linearity of continuous predictors was assessed using fractional polynomials with data grouped if affects were non-linear. All analyses were performed using Stata Version 13.1 (Lakeway Drive, Texas, USA) with 95% confidence intervals (CIs) provided for all estimates.

Results {#Sec6}
=======

Risk of ARMD revision surgery {#Sec7}
-----------------------------

Of 3,340 primary hip replacements undergoing revision surgery for ARMD, 249 (7.5%) had non-MoM bearing surfaces with the remaining 3,091 (92.5%) hips having MoM bearings (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Cumulative number of hip revision procedures performed for ARMD between 2008 and 2015 stratified by the type of primary hip replacement. ARMD = adverse reactions to metal debris; MoM = metal-on-metal; THR = total hip replacement

During the study period a total of 873,188 primary hip replacements were recorded in the NJR where the primary bearing surface could be correctly identified. The risk of ARMD revision surgery in all implanted primary hip replacements was 0.38% (3,340/873,188; 95% CI 0.37--0.40%). The risk of ARMD revision surgery in all non-MoM hip replacements recorded in the NJR was 0.032% (249/789,397; 95% CI 0.028--0.036%) compared to 3.7% (3,091/83,791; 95% CI 3.6--3.8%) in MoM hip replacements (*p* \< 0.001).

When non-MoM hip replacements were subdivided by bearing surface, the risk of ARMD revision surgery by primary bearing surface was: metal-on-polyethylene 0.024% (125/526,951; 95% CI 0.020--0.028%), ceramic-on-ceramic 0.055% (75/135,267; 95% CI 0.044--0.070%), ceramic-on-polyethylene 0.023% (29/124,656; 95% CI 0.016--0.033%), ceramic-on-metal 0.69% (16/2,320; 95% CI 0.39--1.12%), and metal-on-ceramic 1.97% (4/203; 95% CI 0.54--4.97%).

Although ceramic-on-metal and metal-on-ceramic bearings had the highest risk of ARMD revision for all non-MoM bearings, they were implanted in small numbers and are no longer used. When these two non-MoM bearing surfaces were excluded, the risk of ARMD revision in non-MoM hip replacements was dependent on bearing surface and femoral head size. The relative risk of ARMD revision was 2.35 times (95% CI 1.76--3.11) higher in hard-on-hard (ceramic-on-ceramic) compared with hard-on-soft bearing surfaces (metal-on-polyethylene and ceramic-on-polyethylene) (*p* \< 0.001). The relative risk of ARMD revision was 2.80 times (95% CI 1.74--4.36) higher in 36 mm metal-on-polyethylene bearings compared to 28 mm and 32 mm (28/32 mm) metal-on-polyethylene bearings (*p* \< 0.001; Table [1](#Tab1){ref-type="table"}). The risk of ARMD revision was not influenced by femoral head size in both ceramic-on-ceramic and ceramic-on-polyethylene bearing surfaces (Table [1](#Tab1){ref-type="table"}). However, the risk of ARMD revision in both 28/32 mm (0.057%) and 36 mm (0.052%) ceramic-on-ceramic bearings was similar to 36 mm metal-on-polyethylene bearings (0.058%).Table 1Risk of ARMD revision surgery for the three most commonly implanted primary hip replacement bearing surfaces by femoral head sizeHip bearing surfaceFemoral head size (mm)Number of hips implantedNumber of hips revised for ARMDRisk of ARMD revision surgery (%) (95% CI)Relative risk (95% CI) of ARMD revision with 36 mm head size (vs. 28/32 mm)*p*-value (36 mm vs. 28/32 mm for same bearing surface)MoP28 & 32407,412850.021 (0.017--0.026)2.80 (1.74--4.36)\<0.001MoP3646,258270.058 (0.038--0.085)CoC28 & 3261,937350.057 (0.039--0.079)0.92 (0.56--1.51)0.725CoC3667,373350.052 (0.036--0.072)CoP28 & 3296,286240.025 (0.016--0.037)0.82 (0.24--2.19)0.683CoP3624,51350.020 (0.007--0.048)*ARMD* Adverse reactions to metal debris, *CoC* Ceramic-on-ceramic, *CoP* Ceramic-on-polyethylene, *MoP* Metal-on-polyethylene, *CI* Confidence interval

Differences at primary surgery between non-MoM and MoM hips subsequently revised for ARMD (Table [2](#Tab2){ref-type="table"}) {#Sec8}
------------------------------------------------------------------------------------------------------------------------------

Table 2Patient and surgical factors relating to the primary hip replacement procedure in all hips subsequently revised for ARMDCo-variateAll ARMD revisions (*n* = 3340) (100%)ARMD revisions in MoM hips (*n* = 3091) (92.5%)ARMD revisions in non-MoM hips (*n* = 249) (7.5%)*p*-valueOdds ratio (95% CI)Gender Female vs. *male*1,967 (58.89)1,810 (58.56)157 (63.05)0.1650.87 (0.66--1.14)Age (in years)^a^ Mean (SD)58.8 (10.0)58.4 (9.8)63.8 (11.0)\<0.0001  \< 50557 (16.68)534 (17.28)23 (9.24)\<0.001Ref 50--591,113 (33.32)1,061 (34.33)52 (20.88)1.12 (0.67--1.87) 60--691,227 (36.74)1,134 (36.69)93 (37.35)1.81 (1.11--2.93)  ≥ 70443 (13.26)362 (11.71)81 (32.53)4.72 (2.86--7.78)BMI (in kg/m^2^)^b^ Mean (SD)28.3 (4.8)28.3 (4.9)28.3 (4.4)0.978-Primary hip design THR2,359 (70.63)2110 (68.3)249 (100)NA- HR981 (29.37)981 (31.7)0 (0)Bearing surface MoM3,091 (92.54)3091 (100)0 (0)NA- MoP125 (3.74)0 (0)125 (50.20) CoC75 (2.25)0 (0)75 (30.12) CoP29 (0.87)0 (0)29 (11.65) CoM16 (0.48)0 (0)16 (6.43) MoC4 (0.12)0 (0)4 (1.61)Femoral head size (mm) Mean (SD)43.0 (6.4)43.9 (5.7)32.1 (4.0)\<0.0001- Range22.25--6028--6022.25--44 Median444632 Inter-quartile range36--4838--4828--36  ≤ 28143 (4.28)44 (1.42)99 (39.76)\<0.001 3255 (1.65)0 (0)55 (22.09) 36--421,197 (35.84)1,103 (35.68)94 (37.75) 44--481,373 (41.11)1,372 (44.39)1 (0.40) 50--52449 (13.44)449 (14.53)0 (0)  ≥ 54123 (3.68)123 (3.98)0 (0)Cup fixation^b^ Uncemented3,285 (98.73)3,078 (99.96)207 (83.46)\<0.001- Cemented42 (1.26)1 (0.04)41 (16.53)Stem fixation (THR only)^b^ Uncemented2,090 (91.15)1,922 (93.85)168 (68.57)\<0.001- Cemented203 (8.85)126 (6.15)77 (31.43)ASA grade 11,228 (36.77)1,169 (37.82)59 (23.69)\<0.001Ref 21,948 (58.32)1,776 (57.46)172 (69.08)1.61 (1.18--2.20) 3 or above164 (4.91)14 (4.72)18 (7.23)1.68 (0.95--2.97)Indication for surgery Primary OA vs. *other*3,139 (93.98)2,906 (94.01)233 (93.57)0.7790.73 (0.42--1.26)Surgeon grade Consultant vs. *other*2,909 (87.10)2,699 (87.32)210 (84.34)0.177-Complex primary174 (5.21)161 (5.21)13 (5.22)0.993-Surgical approach^b^ Posterior vs. *other*2,241 (69.04)2,109 (70.23)132 (54.32)\<0.001-VTE - chemical LMWH (+/-other)1,673 (50.09)1,524 (49.30)149 (59.84)\<0.001- Aspirin only419 (12.54)401 (12.97)18 (7.23) Other197 (5.90)150 (4.85)47 (18.88) None1,051 (31.47)1,016 (32.87)35 (14.06)VTE - mechanical Any vs. *none*2,919 (87.40)2,690 (87.03)229 (91.97)0.024-Adverse surgical events^c^42 (1.83)35 (1.68)7 (3.30)0.102-*ARMD* Adverse reactions to metal debris, *ASA* American Society of Anesthesiologists, *BMI* Body mass index, *CoC* Ceramic-on-ceramic, *CoM* Ceramic-on-metal, *CoP* Ceramic-on-polyethylene, *CI* Confidence interval, *HR* Hip resurfacing, *LMWH* Low molecular weight heparin, *MoC* Metal-on-ceramic, *MoM* Metal-on-metal, *MoP* Metal-on-polyethylene, *NA* Not applicable, *OA* Osteoarthritis, *Ref* Reference group, *SD* Standard deviation, *THR* Total hip replacement, *VTE* Venous thrombo-embolismValues in brackets are percentages unless otherwise indicated. Statistically significant differences between the two groups (*p* \< 0.05) have been highlighted in bold text^a^Affect of age at primary surgery on outcome was non-linear so variable was grouped^b^Missing data for stated number of hips: BMI (*n* = 2246); surgical approach (*n* = 94); cup fixation (*n* = 13); THR stem fixation (*n* = 66)^c^Intra-operative adverse events included: calcar crack; pelvic and/or femoral shaft penetration; trochanteric and/or femoral shaft fracture; other-Co-variate was not included in multivariable logistic regression model as either it was a surgical factor that is part of the causal pathway, or there was significant missing data

Non-MoM hip patients were significantly older (*p* \< 0.0001) with higher ASA grades (*p* \< 0.001) at primary surgery. Significantly larger femoral head sizes were implanted in MoM hips at primary surgery (femoral head sizes ≥36 mm implanted in 98.6% of MoM hips vs. 38.2% of non-MoM hips; *p* \< 0.001).

Differences at revision surgery between non-MoM and MoM hips revised for ARMD (Table [3](#Tab3){ref-type="table"}) {#Sec9}
------------------------------------------------------------------------------------------------------------------

Table 3Patient and surgical factors relating to the revision hip replacement procedure performed for ARMDCo-variateAll ARMD revisions (*n* = 3340) (100%)ARMD revisions in MoM hips (*n* = 3091) (92.5%)ARMD revisions in non-MoM hips (*n* = 249) (7.5%)*p*-valueOdds ratio (95% CI)Gender Female vs. *male*1,967 (58.89)1,810 (58.56)157 (63.05)0.1650.81 (0.62--1.07)Age (in years)^a^ Mean (SD)64.2 (10.1)64.0 (10.0)67.5 (10.9)\<0.0001  \< 50271 (8.11)255 (8.25)16 (6.43)\<0.001Ref 50--59712 (21.32)672 (21.74)40 (16.06)0.94 (0.51--1.72) 60--691,292 (38.68)1,214 (39.28)78 (31.33)1.17 (0.66--2.06)  ≥ 701,065 (31.89)950 (30.73)115 (46.18)2.34 (1.33--4.12)BMI (in kg/m^2^)^b^ Mean (SD)29.0 (5.2)29.0 (5.2)28.5 (5.3)0.285-Bilateral ARMD revisions282 (8.44)281 (9.09)1 (0.40)\<0.001-Time from primary to revision (in years)^a^ Mean (SD)5.4 (2.1)5.6 (2.0)3.6 (2.9)\<0.0001  ≤ 51,387 (41.53)1,209 (39.11)178 (71.49)\<0.001Ref  \> 51,953 (58.47)1,882(60.89)71 (28.51)0.23 (0.17--0.30)ASA grade 1609 (18.23)569 (18.41)40 (16.06)0.012Ref 22,389 (71.53)2,219 (71.79)170 (68.27)1.01 (0.70--1.47) 3 or above342 (10.24)303 (9.80)39 (15.66)1.70 (1.04--2.78)VTE - chemical LMWH (+/-other)1,798 (53.83)1,644 (53.19)154 (61.85)0.002- Aspirin only92 (2.75)80 (2.59)12 (4.82) Other1,155 (34.58)1,093 (35.36)62 (24.90) None295 (8.83)274 (8.86)21 (8.43)VTE - mechanical Any vs. *none*3,189 (95.48)2,957 (95.66)232 (93.17)0.069-Surgeon grade Consultant vs. *other*3,201 (95.84)2,963 (95.86)238 (95.58)0.833-Surgical approach^b^ Posterior vs. *other*2,691 (81.87)2,516 (82.55)175 (73.22)\<0.001-Revision type Single stage3,266 (97.78)3,034 (98.16)232 (93.17)\<0.001- Staged (2 or more)71 (2.13)54 (1.75)17 (6.83) Excision arthroplasty3 (0.09)3 (0.10)0 (0)Revision indications/intra-operative findings^c^ 1 indication2,080 (62.28)1,988 (64.32)92 (36.95)\<0.001- 2 to 6 indications1,260 (37.72)1,103 (35.68)157 (63.05) ARMD3340 (100)3091 (100)249 (100)NA- Pain665 (19.91)618 (19.99)47 (18.88)0.671- Aseptic loosening338 (10.12)278 (8.99)60 (24.10)\<0.001- Osteolysis255 (7.63)221 (7.15)34 (13.65)\<0.001- Implant malalignment118 (3.53)96 (3.11)22 (8.84)\<0.001- Other indications/findings101 (3.02)98 (3.17)3 (1.20)0.084- Acetabular component wear83 (2.49)46 (1.49)37 (14.86)\<0.001- Dislocation/subluxation67 (2.01)41 (1.33)26 (10.44)\<0.001- Fracture66 (1.98)54 (1.75)12 (4.82)0.003- Infection43 (1.29)33 (1.07)10 (4.02)0.001- Liner dissociation25 (0.75)10 (0.32)15 (6.02)\<0.001- Implant fracture18 (0.54)7 (0.23)11 (4.42)\<0.001- Incorrect implant size17 (0.51)11 (0.36)6 (2.41)0.001-Revision procedure^b,d^ All components revised1,267 (38.79)1,202 (39.62)65 (28.02)\<0.001- Cup (+/- head/liner/taper)1,426 (43.66)1,350 (44.50)76 (32.76) Stem (+/- head/liner/taper)144 (4.41)107 (3.53)37 (15.95) Head/ liner/taper revision only422 (12.92)370 (12.20)52 (22.41)Femoral head size (mm)^b,d^ Mean (SD)34.1 (3.3)34.1 (3.2)33.2 (3.7)0.0003- Range22.25--4822.25--4822.25--40 Median363636 Inter-quartile range32--3632--3632--36  ≤ 321,180 (37.94)1,073 (37.09)107 (49.31)0.001 361,783 (57.33)1,683 (58.17)100 (46.08)  \> 36147 (4.73)137 (4.74)10 (4.61)Bearing surface^b,d^ CoP1,479 (47.6)1,394 (48.4)85 (38.1)\<0.001- CoC885 (28.5)841 (29.2)44 (19.7) MoP736 (23.7)642 (22.3)94 (42.2) CoM3 (0.10)3 (0.10)0 (0) MoM2 (0.06)2 (0.07)0 (0) MoC1 (0.03)1 (0.03)0 (0)Cup fixation^d^ Uncemented2,355 (87.45)2,239 (87.74)116 (82.27)0.057- Cemented338 (12.55)313 (12.26)25 (17.73)Stem fixation^d^ Uncemented867 (61.45)819 (62.57)48 (47.06)0.002- Cemented544 (38.55)490 (37.43)54 (52.94)Bone graft (femoral)^d^107 (3.20)99 (3.20)8 (3.21)0.993-Bone graft (acetabular)^d^650 (19.46)611 (19.77)39 (15.66)0.116-Adverse surgical events^d,e^64 (1.92)48 (1.55)16 (6.43)\<0.001-*ARMD* Adverse reactions to metal debris, *ASA* American Society of Anesthesiologists, *BMI* Body mass index, *CoC* Ceramic-on-ceramic, *CoM* Ceramic-on-metal, *CoP* Ceramic-on-polyethylene, *CI* Confidence interval, *HR* Hip resurfacing, *LMWH* Low molecular weight heparin, *MoC* Metal-on-ceramic, *MoM* Metal-on-metal, *MoP* Metal-on-polyethylene, *NA* Not applicable; *Ref* Reference group, *SD* Standard deviation, *THR* Total hip replacement, *VTE* Venous thrombo-embolismValues in brackets are percentages unless otherwise indicated. Statistically significant differences between the two groups (*p* \< 0.05) have been highlighted in bold text^a^Affect of age at revision surgery on outcome, and affect of time to revision surgery on outcome were non-linear so variables were grouped^b^Missing data for stated number of hips: BMI (*n* = 886); surgical approach (*n* = 53); revision procedure (*n* = 7); femoral head size (*n* = 156); bearing surface (*n* = 160)^c^Intra-operative revision findings refer to a problem with one or both hip components (loosening, fracture etc.)^d^All details about the specific revision surgical procedures performed are provided for the 3266 hips (97.8% of the cohort) undergoing single stage revisions. Therefore details about 74 hip revisions undergoing either 2 or more stages, or excision arthroplasty procedures have not been included^e^Intra-operative adverse events included: calcar crack; pelvic and/or femoral shaft penetration; trochanteric and/or femoral shaft fracture; other- Co-variate was not included in multivariable logistic regression model as either it was a surgical factor that is part of the causal pathway, or there was significant missing data

Revision for ARMD was performed significantly earlier in non-MoM hips compared to MoM hips (mean time from primary to revision surgery 3.6 vs. 5.6 years; *p* \< 0.0001; Fig. [2](#Fig2){ref-type="fig"}). Non-MoM hips were significantly more likely to undergo staged revision procedures than MoM hips (6.8 vs. 1.8%; *p* \< 0.001), and were significantly more likely to have other abnormalities at revision (63.1 vs. 35.7%; *p* \< 0.001), including aseptic component loosening (*p* \< 0.001), osteolysis (*p* \< 0.001), implant malalignment (*p* \< 0.001), dislocation/subluxation (*p* \< 0.001), fracture (*p* = 0.003), and infection (*p* = 0.001). Significantly more intra-operative adverse events (including pelvic and/or femoral shaft penetration/fractures) occurred in non-MoM hips revised for ARMD compared to MoM hips (6.4 vs. 1.6%; *p* \< 0.001).Fig. 2Kaplan Meier ARMD revision rate stratified by the type of primary hip replacement. ARMD = adverse reactions to metal debris; CI = confidence intervals; THR = total hip replacement. The study population all underwent revision of their primary hip replacement implant for ARMD, therefore in the illustrated Kaplan Meier plot all three subgroups ultimately reach a survival probability of zero. This is because complete clinical data for all primary hip replacements not undergoing revision were not available for analysis in this study

Discussion {#Sec10}
==========

Prior to this study it was not known whether ARMD associated with non-MoM hip replacements represented a significant clinical problem. Analysis of the world's largest arthroplasty database has demonstrated that although the risk of revision surgery for ARMD in non-MoM THRs was low, the risk is increasing with one-in-thirteen ARMD revisions performed in non-MoM hip replacements. Furthermore, the risk of ARMD revision was significantly higher in ceramic-on-ceramic THRs and 36 mm metal-on-polyethylene THRs.

Overall risk of revision surgery for ARMD {#Sec11}
-----------------------------------------

The observation that 7.5% of all ARMD revisions were performed in non-MoM THRs is high, especially given the small number of cases reported worldwide \[[@CR20]--[@CR24]\]. Coupled with the annual increasing trend of ARMD revisions in non-MoM THRs these observations are concerning. As only limited reports have been published \[[@CR20]--[@CR24]\] there is currently a relative lack of awareness amongst clinicians that ARMD associated with non-MoM hips represents a significant problem. Therefore our findings are likely to be influenced by surveillance bias and the true ARMD revision risk is potentially underestimated. The number of ARMD revisions performed in MoM hips were also heavily influenced by surveillance bias given revisions increased considerably between 2010 and 2013, which reflects widespread recognition of this problem and the implementation of regular patient follow-up \[[@CR16], [@CR17]\]. If closer surveillance is deemed necessary for non-MoM THRs \[[@CR7]\], the risk of ARMD revision is expected to increase at a greater rate than presently.

The risk of ARMD revision in the three commonest non-MoM bearing surfaces appears low (0.023--0.055%) as this entity is not well recognised and the overall number of THRs implanted is very large. However, the risk of ARMD revision in MoM hips in 2015 (3.7%) has increased 25-fold compared to that reported in 2009 (0.15%), when little was known about ARMD in MoM hips \[[@CR27]\]. Although we suspect the risk of ARMD revision in non-MoM hips will not reach levels observed in MoM hips, the risk may increase at a similar rate.

ARMD risk by bearing surface and femoral head size {#Sec12}
--------------------------------------------------

ARMD revisions were performed in all commonly implanted non-MoM bearing surfaces and all femoral head sizes. However, the risk of ARMD revision was 2.35 times higher in ceramic-on-ceramic bearings compared with hard-on-soft bearings, and 2.80 times higher in 36 mm metal-on-polyethylene bearings compared to smaller metal-on-polyethylene THRs.

Ceramic-on-ceramic THRs became popular for treating young and active patients with hip arthritis, especially since high failure rates associated with MoM bearings were recognised \[[@CR18], [@CR19]\]. Analysis of NJR data in 2012 observed low all-cause revision rates in large-diameter ceramic-on-ceramic bearings, therefore the continued use of ceramic-on-ceramic THRs with large femoral head sizes was recommended \[[@CR8]\]. By contrast, with regard to the risk of ARMD revision our data demonstrates that ceramic-on-ceramic THRs have a significantly higher relative risk compared to metal-on-polyethylene and ceramic-on-polyethylene bearings. When choosing bearing surfaces for primary THR we recommend surgeons carefully consider the competing risks of all-cause versus ARMD revision, the potentially devastating complication of ARMD \[[@CR10], [@CR15]\], and acknowledge that ARMD revision rates in non-MoM THRs may be much higher than we have reported due to a lack of patient surveillance and incorrect surgeon reporting. However, our findings do not support the use of ceramic-on-ceramic THRs of any head size over hard-on-soft bearings if the risk of ARMD revision is to be minimised.

Metal-on-polyethylene remains the most commonly implanted THR bearing worldwide \[[@CR18], [@CR19]\]. Recently larger head sizes have been implanted to reduce dislocation risk and potentially reduce wear. Our observations suggest 36 mm metal-on-polyethylene bearings have a significantly increased risk of ARMD revision compared to smaller sizes, and an ARMD risk similar to ceramic-on-ceramic bearings. Therefore we recommend against using 36 mm or above metal-on-polyethylene THRs if smaller bearings can safely be implanted. The risk of ARMD revision was low in 28/32 mm and 36 mm ceramic-on-polyethylene THRs suggesting it could be safe to use 36 mm femoral heads with ceramic-on-polyethylene THRs. However, definitive conclusions cannot be drawn given much fewer 36 mm ceramic-on-polyethylene THRs were implanted compared to ceramic-on-ceramic and metal-on-polyethylene THRs.

Mechanisms for findings {#Sec13}
-----------------------

Although we have some understanding of the mechanisms underlying ARMD development in MoM hips \[[@CR12]--[@CR14]\], we currently do not understand why ARMD occurs in non-MoM THRs which is extremely concerning. Some implicate corrosion at modular implant junctions (femoral head-neck junction and femoral neck-stem junction) \[[@CR20]--[@CR24]\], with corrosion occurring due to articulating mixed alloys, such as metal femoral heads with titanium femoral necks \[[@CR28]\]. Ceramic-on-ceramic bearings may develop ARMD because of high friction causing metal debris at the trunnion and/or other modular junctions. Large metal-on-polyethylene bearings may be increasingly prone to wear and corrosion at the femoral head-neck junction and/or other modular junctions because of increased transmitted torques from larger heads \[[@CR8]\]. Further research is needed to establish why ARMD develops in non-MoM THRs.

Primary surgery factors {#Sec14}
-----------------------

Numerous differences existed between non-MoM and MoM hip patients at primary surgery. These relate to the inherent selection bias for undergoing each procedure \[[@CR9]\] and are factors causally related to the primary procedure, rather than truly clinically significant differences in ARMD revision between different bearing surfaces.

Revision surgery factors {#Sec15}
------------------------

ARMD revisions were performed significantly earlier in non-MoM THRs compared to MoM hips. This is concerning given MoM hips have high short-term failure rates \[[@CR8], [@CR9]\]. We can only speculate reasons for this difference. In addition to ARMD, non-MoM THRs had significantly more abnormal findings at revision compared to MoM hips. A number of these (aseptic loosening, osteolysis, implant malalignment) are readily identifiable on hip radiographs. The presence of such abnormalities at an early stage of investigation may have contributed towards earlier revision compared to MoM hips, with ARMD subsequently diagnosed at revision surgery. Another explanation relates to the disease process. It is possible that ARMD due to corrosion is more aggressive than ARMD developing from high bearing wear, with evidence in MoM hips supporting much higher failure rates in THRs compared to hip resurfacings even with identical bearing surfaces \[[@CR14], [@CR18]\]. However this requires further investigation, including implant retrieval and histopathological analysis.

Non-MoM THRs more commonly underwent staged revisions compared to MoM hips. As registries do not record histopathological data we can again only speculate an explanation for this observation. Given surgeons are presently less aware of ARMD associated with non-MoM THRs compared to MoM hips, and that the intra-operative appearances of ARMD can be similar to those seen with infection, it is possible that surgeons were more likely to elect to treat failing non-MoM THRs with staged revisions rather than in a single stage. Staged revisions in non-MoM THRs may also have been preferable given these hips had significantly more abnormal findings at revision which may have required major reconstruction.

The observation that non-MoM THRs have significantly more adverse events at revision surgery is also concerning. This may again relate to the increased number of abnormalities at revision in non-MoM hips making the surgery more complex. Furthermore, it is expected that removing a well-fixed corroded femoral component in non-MoM THRs is more likely to be associated with complications, such as fracture, compared with removing MoM hip resurfacings which conserve femoral bone. Revision of MoM hips for ARMD has resulted in generally poor short-term outcomes \[[@CR15]\]. Given that non-MoM THRs had more abnormal findings and adverse events at revision surgery compared to MoM hips, it is hypothesised they may have poor short-term outcomes. However limited evidence is currently available \[[@CR24]\], therefore future studies must establish outcomes following ARMD revision in non-MoM THRs.

Strengths {#Sec16}
---------

Study strengths include the dataset coming from the worlds largest arthroplasty registry which uses linked data to ensure procedures performed at different institutions were captured, with almost complete compliance now reported \[[@CR29]\]. Only small case series are presently available \[[@CR20]--[@CR24]\], therefore our study contributes significantly to the literature. Furthermore, by reporting on the whole population our study is not subject to sampling bias. Given the cohort size and that THR is so common worldwide with similar bearing surfaces and femoral head sizes implanted \[[@CR3], [@CR19]\], it is suspected our findings have good external validity and generalisability, though this requires formal validation.

Limitations {#Sec17}
-----------

Although our study is large, it is based on observational data therefore it is difficult to infer causality. However, we have provided explanations for our findings based on the literature and suggested important future research. The risk of ARMD revision in non-MoM hips reported here is likely to be an underestimate given surgeons may not have been aware of this problem with these bearings, and therefore incorrectly coded revisions using other indications, such as infection. It is also possible some ARMD revisions were performed but not recorded which would also underestimate the problem \[[@CR30]\]. Surgeons may also have different thresholds for diagnosing ARMD at revision surgery, which may influence the study findings. It was not possible to confirm the diagnosis of ARMD histopathologically using registry data. Although this is an important limitation of the present study, we recommend future prospective studies based on non-registry cohorts report details of their histopathological analysis and confirm the diagnosis of ARMD. As ARMD can be difficult to distinguish from infection by the surgeon at the time of revision, it is also possible that given the lack of histopathological data some staged and non-staged ARMD revisions may actually have been for infection rather than ARMD. Therefore the risk of ARMD revision in non-MoM THRs may have been overestimated here. Finally, it was not possible to access data regarding the specific hip implant designs given this is considered sensitive information by the NJR and manufacturers. However we recognise the importance of analysing this given the significant changes recently made to THR designs.

Conclusions {#Sec18}
===========

We observed a significant proportion (7.5%) of all ARMD revisions occur in non-MoM THRs. Although the overall risk of ARMD revision surgery in non-MoM THRs appears low, it is increasing, and is significantly higher in ceramic-on-ceramic THRs and in 36 mm metal-on-polyethylene THRs. Compared to MoM hips, non-MoM THR ARMD revisions were performed significantly earlier and had significantly more abnormalities and adverse events at revision surgery. ARMD associated with non-MoM THRs may represent a significant clinical problem that will become more apparent with time. For primary THR we recommend using hard-on-soft bearings with 28/32 mm femoral heads where possible, as this will minimise the clinical impact of ARMD in non-MoM hips. Further work is needed to establish whether ARMD development in non-MoM THRs is specific to certain implant designs.

ARMD

:   Adverse reactions to metal debris

ASA

:   American Society of Anesthesiologists

CI

:   confidence interval

MoM

:   metal-on-metal

NJR

:   National Joint Registry

non-MoM THR

:   non-metal-on-metal total hip replacement

THR

:   total hip replacement

The authors would like to thank Arthritis Research UK and The Orthopaedics Trust who have provided one of the authors with funding to undertake this research. We also thank the patients and staff of all the hospitals in England, Wales and Northern Ireland who have contributed data to the National Joint Registry. We are grateful to the Healthcare Quality Improvement Partnership (HQIP), the NJR Research Sub-Committee and staff at the NJR Centre for facilitating this work. The authors have conformed to the NJR's standard protocol for data access and publication. The views expressed represent those of the authors and do not necessarily reflect those of the National Joint Registry Steering Committee or the Health Quality Improvement Partnership (HQIP) who do not vouch for how the information is presented. The Healthcare Quality Improvement Partnership ("HQIP") and/or the National Joint Registry ("NJR") take no responsibility for the accuracy, currency, reliability and correctness of any data used or referred to in this report, nor for the accuracy, currency, reliability and correctness of links or references to other information sources and disclaims all warranties in relation to such data, links and references to the maximum extent permitted by legislation.

Funding {#FPar1}
=======

One author (GM) received funding from Arthritis Research UK (Grant reference number 21006) and The Orthopaedics Trust to undertake the work contained within this manuscript. These funders had no role in the study design, data collection, analysis and interpretation, decision to publish, or preparation of the manuscript.

Availability of data and materials {#FPar2}
==================================

We are unable to provide access to the dataset used for this manuscript. We received the dataset from the National Joint Registry in pseudo-anonymised form. This data is confidential/sensitive and not owned by the authors of the manuscript. If the journal wishes to access the data they will need to apply directly to the National Joint Registry as per their standard terms of data release. Further details regarding data access can be found at (<http://www.njrcentre.org.uk/njrcentre/Research/Researchrequests/tabid/305/Default.aspx>).

Authors' contributions {#FPar3}
======================

GM was involved in the design of the study, performed the data analysis and interpretation, and drafted and revised the manuscript. HP was involved in the design of the study, assisted with the data interpretation, and revised the manuscript for important intellectual content. DM was involved in the design of the study, assisted with the data interpretation, and revised the manuscript for important intellectual content. AJ was involved in the design of the study, assisted with the data analysis and interpretation, and revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Competing interests {#FPar4}
===================

GM has received financial support from Arthritis Research UK and The Orthopaedics Trust to undertake research work, which includes the work presented in this manuscript. GM has also received funding to undertake other research work from The Royal College of Surgeons of England, and The Royal Orthopaedic Hospital Hip Research and Education Charitable Fund.

HP is a paid consultant and speaker for Zimmer-Biomet (manufacturer of orthopaedic implants), who have paid expenses for attending courses and meetings. Research funding from Zimmer-Biomet and Stryker (manufacturer of orthopaedic implants) has been paid to HP's institution for other research work.

DM is a paid consultant and speaker for Zimmer-Biomet, who have paid expenses for attending courses and meetings. DM receives royalties related to an Orthopaedic knee replacement manufactured by Zimmer-Biomet. Research funding from Zimmer-Biomet and Stryker has been been paid to DM's institution for other research work.

AJ is a member of the BMC Musculoskeletal Disorders journal editorial board (Associate Editor). AJ has received consultancy, lecture fees and honoraria from Servier, UK Renal Registry, Oxford Craniofacial Unit, IDIAP Jordi Gol, Freshfields Bruckhaus Deringer, is a member of the Data Safety and Monitoring Board (which involved receipt of fees) from Anthera Pharmaceuticals, INC., and received consortium research grants from ROCHE. None of these payments were related to the work presented in this manuscript.

Consent for publication {#FPar5}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar6}
==========================================

This study did not require ethical approval as the analysis was performed on a national clinical dataset. However, all patients within the dataset provide individual consent to the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man for use of their data for a number of purposes, which includes research. A formal application was submitted to, and approved by, the National Joint Registry to use the relevant dataset.
